Antibody-Drug Conjugates SOT106
SOTIO is developing SOT106, an ADC against leucine-rich repeat containing 15 (LRRC15). SOT106 is a novel ADC based on SOTIO Biotech’s proprietary antibody and LigaChem Biosciences (former LegoChem) industry-leading ConjuAllTM ADC platform technology (learn more here).
SOT106 is currently in advanced preclinical development against solid tumor indications, with a particular focus on soft tissue sarcoma and osteosarcoma. It shows potential for best-in-class efficacy, safety, and tolerability, leading to a beneficial therapeutic index. In preclinical studies, SOT106 has demonstrated excellent preclinical efficacy in mesenchymal tumors, including a broad subset of sarcomas, and has displayed a favorable pharmacokinetic and safety profile, good stability in vivo, and a high therapeutic index.
SOT106 offers a novel precision approach with broad applicability in LRRC15+ sarcomas and other solid tumors.
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
Zuidplein 168
1077 XV Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
